- Profile
- prev
- next
General
-
Headquarters
Newton, Massachusetts, United States of America
-
Founders & Team
Hazel Szeto
-
Year Founded
2007
-
Company type
Public company
-
Stock Ticker
MITO
-
Funding stage
IPO
-
Total funding ($M)
120
-
Investors
Morningside Venture Investments, Kingdon Capital
Technical Details
-
Aging Target
Mitochondrial dysfunction
-
Disease indication
Barth syndrome, eye degeneration, Alzheimer’s,Parkinson’s disease, Leigh’s syndrome, Friedreich’s ataxia
-
Product modality
peptides, small molecules
-
Clinical stage
Phase 2 Trials
-
Product names
Etamipretide, SBT-272, SBT-259, SBT-550
Stealth BioTherapeutics is an innovative biopharmaceutical company committed to bringing patients mitochondrial targeted therapies to treat both common and rare diseases. Driven by a desire to help patients with unmet treatment needs, our team collaborates with well-recognized institutions, physicians and scientists to develop the next generation of therapies focusing on mitochondrial dysfunction in many diseases.